Full View

Evaluating primary endpoints for COVID-19 therapeutic trials to assess recovery

DJ Douin, L Siegel, G Grandits, A Phillips… - American journal of …, 2022 - atsjournals.org
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …
被引用次数：13 相关文章

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits… - American Journal of …, 2022 - research.monash.edu
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits, A Phillips… - American Journal of …, 2022 - discovery.ucl.ac.uk
RATIONALE: Uncertainty regarding the natural history of coronavirus disease 2019 (COVID-
19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits… - … of respiratory and …, 2022 - pubmed.ncbi.nlm.nih.gov
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits… - American Journal of …, 2022 - research.regionh.dk
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …
[HTML] nih.gov

[HTML][HTML] Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits, A Phillips… - American Journal of …, 2022 - ncbi.nlm.nih.gov
Objectives Evaluate 90-day clinical course of patients hospitalized with COVID-19,
comparing three distinct definitions of recovery. Methods We used pooled data from three …

Evaluating primary endpoints for COVID-19 therapeutic trials to assess recovery

DJ Douin, L Siegel, G Grandits, A Phillips… - American Journal of …, 2022 - dr.ntu.edu.sg
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.

DJ Douin, L Siegel, G Grandits… - American Journal of …, 2022 - search.ebscohost.com
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

DJ Douin, L Siegel, G Grandits… - … of respiratory and …, 2022 - hsrc.himmelfarb.gwu.edu
RATIONALE: Uncertainty regarding the natural history of coronavirus disease 2019 (COVID-
19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes …

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.

DJ Douin, L Siegel, G Grandits, A Phillips… - American journal of …, 2022 - escholarship.org
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …